Alaunos Therapeutics (TCRT) Stock: Buy, Sell, or Hold?
TCRT - Alaunos Therapeutics, Inc. Common Stock
$1.02
-0.07 (-6.42%)
▼
5d:
-19.05%
30d:
-38.55%
90d:
-56.96%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When TCRT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TCRT is down 19.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TCRT is down 19.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TCRT is currently trading at $1.02, which is considered oversold relative to its 30-day fair value range of $1.26 to $1.72.
Technical Outlook: Technically, TCRT is in a strong downtrend. Immediate support is located at $0.97, while resistance sits at $1.65. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: TCRT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.75 (+71.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TCRT is in a strong downtrend. Immediate support is located at $0.97, while resistance sits at $1.65. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: TCRT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.75 (+71.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.26 -
$1.72
Company Quality Score
43/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BEARISH: Downward momentum (-6.4%)
- BULLISH: Trading 71.6% below Wall St target ($1.75)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.72
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.97
Resistance Level
$1.65
Current Trend
Strong Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.48
Wall Street Target
$1.75
(+71.6%)
Revenue Growth (YoY)
-25.0%
Share & Embed Analysis
Last updated: September 29, 2026 9:19 AM ET
Data refreshes hourly during market hours. Next update: 10:19 AM
Data refreshes hourly during market hours. Next update: 10:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 45 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 59 HOLD |
